# Rifamycin in Minimal Hepatic Encephalopathy

> **NCT04082780** · PHASE2 · COMPLETED · sponsor: **Hunter Holmes Mcguire Veteran Affairs Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Hepatic Encephalopathy
- Cirrhosis, Liver

## Interventions

- **DRUG:** Rifamycin SV MMX
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04082780
- **Lead sponsor:** Hunter Holmes Mcguire Veteran Affairs Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2023-04-28
- **Final completion:** 2023-04-28
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04082780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04082780, "Rifamycin in Minimal Hepatic Encephalopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04082780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*